Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Scientific Officer | June 11, 2019 | June 13, 2019 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 11, 2019 · Filed June 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 33,729 |
Reported balance
After 2019-06-11 transaction · row 1
1 source rowRow 1 · 2019-06-11 · Exercise / conversion · Acquired 7,218 · Balance 33,729 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2022-04-05 | Direct | 0 |
Reported balance
After 2019-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-06-11 · Exercise / conversion · Disposed 7,218 · Balance 0 F2: This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015. |
| Common stockSEC Table I · non-derivative | IndirectSee footnote | 53,059 |
Reported balance
Holding disclosure · report date 2019-06-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 53,059 F1: Shares held by a trust, of which the reporting person is trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by a trust, of which the reporting person is trustee and beneficiary.
F2: This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015.
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2018 Filed Aug 8, 2018 20:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 600 | $80.87 | $48,522.00 |
DisclosureSEC source: 0001209191-18-045820 · doc4.xml · nonDerivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.64 to $81.01. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 20:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,100 | $80.15 | $168,315.00 |
DisclosureSEC source: 0001209191-18-045820 · doc4.xml · nonDerivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,796 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.53 to $80.45. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 20:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 300 | $78.32 | $23,496.00 |
DisclosureSEC source: 0001209191-18-045820 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,896 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.01 to $78.53. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 20:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,000 | $9.05 | $27,150.00 |
DisclosureSEC source: 0001209191-18-045820 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-041982 · doc4.xml · derivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 300 | $84.32 | $25,296.00 |
DisclosureSEC source: 0001209191-18-041982 · doc4.xml · nonDerivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $84.07 to $84.69. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,700 | $83.41 | $225,207.00 |
DisclosureSEC source: 0001209191-18-041982 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,496 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $83.01 to $83.68. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,000 | $9.05 | $27,150.00 |
DisclosureSEC source: 0001209191-18-041982 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 05, 2018 Filed Aug 10, 2018 21:20 UTC Amendment | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-046269 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-036320 · doc4.xml · derivative · entry 5 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 939 | $94.28 | $88,528.92 |
DisclosureSEC source: 0001209191-18-036320 · doc4.xml · nonDerivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $94.13 to $94.45. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,259 | $93.27 | $117,426.93 |
DisclosureSEC source: 0001209191-18-036320 · doc4.xml · nonDerivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,135 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $92.96 to $93.79. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 802 | $92.45 | $74,144.90 |
DisclosureSEC source: 0001209191-18-036320 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,394 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $91.90 to $92.87. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,000 | $9.05 | $27,150.00 |
DisclosureSEC source: 0001209191-18-036320 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 05, 2018 Filed Aug 10, 2018 21:19 UTC Amendment | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-046268 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 15,177 | $0.00 Strike: $31.64 | $0.00 |
DisclosureSEC source: 0001209191-18-033646 · doc4.xml · derivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,862 Underlying: Common stock · 15,177 shares Expires 2024-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 15,177 | $90.00 | $1,365,930.00 |
DisclosureSEC source: 0001209191-18-033646 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 15,177 | $31.64 | $480,200.28 |
DisclosureSEC source: 0001209191-18-033646 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 23, 2018 Filed Aug 10, 2018 21:19 UTC Amendment | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 15,177 | $0.00 Strike: $31.64 | $0.00 |
DisclosureSEC source: 0001209191-18-046266 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,862 Underlying: Common stock · 15,177 shares Expires 2024-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 07, 2018 Filed May 8, 2018 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-028538 · doc4.xml · derivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| May 07, 2018 Filed May 8, 2018 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 3,000 | $81.81 | $245,430.00 |
DisclosureSEC source: 0001209191-18-028538 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.30 to $82.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2018 Filed May 8, 2018 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,000 | $9.05 | $27,150.00 |
DisclosureSEC source: 0001209191-18-028538 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 07, 2018 Filed Aug 10, 2018 21:18 UTC Amendment | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-046265 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · derivative · entry 6 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 500 | $77.17 | $38,585.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · nonDerivative · entry 5 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.70 to $77.64. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 800 | $76.17 | $60,936.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · nonDerivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,696 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $75.69 to $76.64. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 400 | $75.04 | $30,016.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · nonDerivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,496 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $74.68 to $75.38. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,300 | $73.90 | $96,070.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,896 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $73.41 to $74.39. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,000 | $9.05 | $27,150.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 05, 2018 Filed Aug 10, 2018 21:17 UTC Amendment | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-046264 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 4,100 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001209191-18-022211 · doc4.xml · derivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,718 Underlying: Common stock · 4,100 shares Expires 2022-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 37 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-18-022211 · doc4.xml · derivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,766 Underlying: Common stock · 37 shares Expires 2020-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 4,100 | $2.34 | $9,594.00 |
DisclosureSEC source: 0001209191-18-022211 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 37 | $0.47 | $17.30 |
DisclosureSEC source: 0001209191-18-022211 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2018 Filed Aug 10, 2018 21:16 UTC Amendment | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 4,100 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001209191-18-046262 · doc4a.xml · derivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,718 Underlying: Common stock · 4,100 shares Expires 2022-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015. Read SEC document |
| March 28, 2018 Filed Aug 10, 2018 21:16 UTC Amendment | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 37 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-18-046262 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,766 Underlying: Common stock · 37 shares Expires 2020-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F2 · derivative.exercise_date: This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · derivative · entry 6 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,100 | $84.10 | $92,510.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · nonDerivative · entry 5 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,059 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $83.66 to $84.65. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,100 | $83.21 | $91,531.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · nonDerivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,159 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $82.65 to $83.57. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 400 | $82.04 | $32,816.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · nonDerivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,259 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.53 to $82.36. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 400 | $80.93 | $32,372.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,659 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.49 to $81.35. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,000 | $9.05 | $27,150.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011242 · doc4.xml · derivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common stock · 8,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 33,000 | $0.00 Strike: $77.70 | $0.00 |
DisclosureSEC source: 0001209191-18-011242 · doc4.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common stock · 33,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 2,936 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · derivative · entry 8 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,154 Underlying: Common stock · 2,936 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock options (right to buy) · Derivative | 64 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · derivative · entry 7 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,803 Underlying: Common stock · 64 shares Expires 2020-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 400 | $78.03 | $31,212.00 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · nonDerivative · entry 6 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,059 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $77.63 to $78.45. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 701 | $76.76 | $53,808.76 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · nonDerivative · entry 5 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,459 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.44 to $77.20. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,100 | $75.70 | $83,270.00 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · nonDerivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,160 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $75.31 to $76.26. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 799 | $74.89 | $59,837.11 |
DisclosureSEC source: 0001209191-18-008108 · doc4.xml · nonDerivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,260 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $74.16 to $75.06. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.